KNSA
Kiniksa Pharmaceuticals Ltd
Price:  
22.61 
USD
Volume:  
595,003.00
Bermuda | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

KNSA WACC - Weighted Average Cost of Capital

The WACC of Kiniksa Pharmaceuticals Ltd (KNSA) is 6.7%.

The Cost of Equity of Kiniksa Pharmaceuticals Ltd (KNSA) is 9.70%.
The Cost of Debt of Kiniksa Pharmaceuticals Ltd (KNSA) is 5.00%.

Range Selected
Cost of equity 7.40% - 12.00% 9.70%
Tax rate 26.20% - 27.00% 26.60%
Cost of debt 5.00% - 5.00% 5.00%
WACC 5.5% - 7.8% 6.7%
WACC

KNSA WACC calculation

Category Low High
Long-term bond rate 3.9% 4.4%
Equity market risk premium 4.6% 5.6%
Adjusted beta 0.77 1.28
Additional risk adjustments 0.0% 0.5%
Cost of equity 7.40% 12.00%
Tax rate 26.20% 27.00%
Debt/Equity ratio 1 1
Cost of debt 5.00% 5.00%
After-tax WACC 5.5% 7.8%
Selected WACC 6.7%